Jeremy Braybrooke

Honorary Associate Professor

University of Bristol

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Jeremy Braybrooke is an Honorary Associate Professor at the University of Bristol. His research focuses on breast cancer, particularly on recurrence rates, treatment efficacy, and the use of chemotherapy and hormonal therapies in early-stage and advanced cases. He has contributed to numerous studies, including analyses on anthracyclines and aromatase inhibitors, and has been involved in significant clinical trials aimed at improving patient outcomes in breast cancer therapies.

Articles (18)

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (21)

Daniel Rea

Professor of Medical Oncology

University of Birmingham

UNITED KINGDOM

Jeremy Braybrooke

Research Interests

Explore related searches

Contact this professor

About

Articles (18)

The PARTNER trial of neoadjuvant olaparib in triple-negative breast cancer.

Benefits and risks of anthracyclines in early-stage breast cancer – Authors' reply

Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155 746 women in 151 trials.

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Radiotherapy to regional nodes in early breast cancer: individual-patient-data meta-analysis of 14,324 women in 16 trials

Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.

Expert UK consensus on the definition of high risk of recurrence in HER2-negative early breast cancer: A modified Delphi panel

Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST).

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group.

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials.

Adjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast Cancer.

Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials.

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer.

Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group.

Trastuzumab Beyond Progression in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: UK Practice now and in the Future.

Collaborators (21)

Daniel Rea

Sheeba Irshad

Marta Santisteban

Robert Hills

Iain Macpherson

Helena Earl

Jonas Bergh

Francesca Holt

Pericles Foroglou

Marc van de Vijver

Ashish Sharma

Gurdeep S Mannu

Juan Rafael de la Haba Rodríguez

Francesco Ciompi

Amy Lo

Lucy Gettins

MONICA ARNEDOS

Peter Lucas

Elizabeth James

Karen Willard-Gallo

John Le Quesne

Make your next move.